Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

WPD Pharmaceuticals Inc. (8SV1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.03760.0000 (0.00%)
At close: 08:13AM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0376
Open0.0376
Bid0.0376 x N/A
Ask0.0600 x N/A
Day's Range0.0376 - 0.0376
52 Week Range0.0160 - 0.1890
Volume1,100
Avg. Volume972
Market Cap4.265M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.0310
Earnings DateNov 29, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 8SV1.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences

      VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences (“WFUHS”). On April 22, 2022 WPD Pharmaceuticals Sp. z o.o. (“WPD Poland”), the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2, WPD signed An

    • GlobeNewswire

      WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

      Expert research team aiming to optimize the effects of radiotherapy of brain tumorsVANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has received the final version of the signed Consortium Agreement related to the EuroNanoMed Project. The consortium will research the potential of AGuIX® nanoparticles in maximizing radiotherapy efficiency a

    • GlobeNewswire

      WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary

      VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”) has approved a plan to restructure (the “Restructuring”) the outstanding capitalization of the Company’s wholly owned Polish subsidiary WPD Pharmaceuticals sp. z.o.o. (“WPD Poland”). Due to the occurrence of negative shareholders’ equity in WPD Poland, under Polish corporate law, WPD Poland is obliga

    Advertisement
    Advertisement